Efferon, an Austrian biotech company, raised €4.3 million in Seed funding from existing private investors in the DACH region. The company develops hemoadsorption devices that remove endotoxins and excessive inflammatory mediators from the bloodstream. Its technology is used in critical care settings such as sepsis and septic shock.
Funding details
The new funding brought Efferon's total raised to €6.8 million. The money will support commercial expansion in Europe, India, and Latin America. It will also fund distributor network development, regulatory work, and clinical evidence.
Company reach
Efferon operates in 46 countries with a network of 21 distributors. It has completed more than 30,000 treatments. The company reported revenue above €1.1 million in 2025.
Technology and expansion
Efferon LPS and Efferon NEO target systemic inflammation directly from the bloodstream. The devices are approved and used across Europe. The company plans to combine commercial distribution in India with real-world data collection on adoption and training.
The company expects its intensive care products to reach approximately €5 million in revenue by 2027. The company said outpatient products could add up to €3 million after successful registration. Efferon also aims to build a foundation for a full Series A round and further regulatory progress in the United States.